Novo Nordisk plans to acquire Dicerna Pharmaceuticals for $3.3 billion, a move that will net Novo Nordisk a ribonucleic acid interference (RNAi) platform for identifying genes that can be targeted to develop drug candidates across many therapeutic areas.
Source: Drug Industry Daily